Klaricid

Clarithromycin, the active ingredient in Klaricid, is a macrolide presented as an intravenous solution for intravenous use. It treats a range of bacterial infections in adults and children when administered by infusion.

GNH USA supplies Klaricid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Clarithromycin is a macrolide antibiotic used to treat infections caused by susceptible bacteria. - Community‑acquired pneumonia: effective against typical and atypical pathogens, improving respiratory function. - Skin and soft‑tissue infections: eradicates susceptible Gram‑positive and some Gram‑negative organisms. - Upper respiratory tract infections: reduces bacterial load and alleviates symptoms.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate intensity. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - QT prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Clostridioides difficile‑associated diarrhea: severe colitis. - Arrhythmias: ventricular tachycardia or fibrillation. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.

Clarithromycin should be used with caution in specific clinical situations. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes before and during treatment. - Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances. - Drug interactions: review concomitant medications for potential CYP3A4 effects. - Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Clarithromycin interacts with several drugs; careful assessment is required. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase clarithromycin levels. - QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of arrhythmia. - Ergot alkaloids (e.g., ergotamine): risk of ergotism. Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - Theophylline: may raise plasma concentrations, causing toxicity. - Statins (especially simvastatin): increased risk of myopathy.